Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors

Marc Oliva, John Powderly, Christophe Le Tourneau, Amani Makkouk, Philippe A. Cassier, Maulik Patel, Ki Chung, Alexander Spira, Amita Patnaik, Wu-Chou Su, Toshihiko Doi, Victor Moreno, Chia-Chi Lin, Toshio Shimizu, Sonali Jindal, Padmanee Sharma, Agostina Stradella, Jaehyung Hong, John Engelhardt, Martha Blaney, Tolga Turan, Luija Wang, Michael A. McDevitt, A. Dimitrios Colevas

Open source

DOI: 10.1080/14796694.2026.2736946
Published: 2026-09-26
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2736946,
  title = {Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors},
  author = {Marc Oliva and John Powderly and Christophe Le Tourneau and Amani Makkouk and Philippe A. Cassier and Maulik Patel and Ki Chung and Alexander Spira and Amita Patnaik and Wu-Chou Su and Toshihiko Doi and Victor Moreno and Chia-Chi Lin and Toshio Shimizu and Sonali Jindal and Padmanee Sharma and Agostina Stradella and Jaehyung Hong and John Engelhardt and Martha Blaney and Tolga Turan and Luija Wang and Michael A. McDevitt and A. Dimitrios Colevas},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2736946},
  url = {https://doi.org/10.1080/14796694.2026.2736946}
}

RIS

TY  - JOUR
TI  - Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors
AU  - Marc Oliva
AU  - John Powderly
AU  - Christophe Le Tourneau
AU  - Amani Makkouk
AU  - Philippe A. Cassier
AU  - Maulik Patel
AU  - Ki Chung
AU  - Alexander Spira
AU  - Amita Patnaik
AU  - Wu-Chou Su
AU  - Toshihiko Doi
AU  - Victor Moreno
AU  - Chia-Chi Lin
AU  - Toshio Shimizu
AU  - Sonali Jindal
AU  - Padmanee Sharma
AU  - Agostina Stradella
AU  - Jaehyung Hong
AU  - John Engelhardt
AU  - Martha Blaney
AU  - Tolga Turan
AU  - Luija Wang
AU  - Michael A. McDevitt
AU  - A. Dimitrios Colevas
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2736946
UR  - https://doi.org/10.1080/14796694.2026.2736946
ER  -

APA

Oliva, M., Powderly, J., Tourneau, C. L., Makkouk, A., Cassier, P. A., Patel, M., Chung, K., Spira, A., Patnaik, A., Su, W., Doi, T., Moreno, V., Lin, C., Shimizu, T., Jindal, S., Sharma, P., Stradella, A., Hong, J., Engelhardt, J., Blaney, M., Turan, T., Wang, L., McDevitt, M. A., & Colevas, A. D. (2026). Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors. Future Oncology. https://doi.org/10.1080/14796694.2026.2736946

Source records

crossref · retrieved 2026-11-10T14:35:26.377Z